

# XXXIV MEETING OF THE CLUB JULES GONIN




CLUB JULES GONIN

---

MALLORCA - SPAIN | 22-25 MAY 2024

---

## PRELIMINARY PROGRAMME



# Welcome to the XXXIV Meeting Of The Club Jules Gonin

---

Dear Colleagues.

It is our great pleasure to invite you to Palma de Mallorca for the XXXIV Meeting of the Club Jules Gonin.

The island is well served by airlines, and it is thus an excellent location for a meeting of the Club Jules Gonin.

We very much look forward to seeing you in Mallorca in May 2024.



CLUB JULES GONIN

**José García Arumí**

President, Club Jules Gonin

**Thomas J. Wolfensberger**

Secretary, Club Jules Gonin

## Committees

### Executive Committee

#### President

José García-Arumí

#### Secretary

Thomas J. Wolfensberger

#### Members

Frank G. Holz

Jørgen Krohn

David Steel

Ramin Tadayoni

Hiroko Terasaki

Cynthia Toth

Lihteh Wu

### Scientific Programme Committee

#### Chairman

José García-Arumí

#### Members

Frank G. Holz

David Steel

Ramin Tadayoni

Cynthia Toth

Thomas J. Wolfensberger

Lihteh Wu

# How to reach Palma

## By air

The fastest and most comfortable way to get to the island is by air since Mallorca is connected with 177 destinations.

Son Sant Joan Airport is the third most important airport in Spain, from other Spanish airports and countries such as Germany and the United Kingdom.

Palma Airport, or PMI (IATA airport code), is the main point of entry for visitors arriving to Mallorca. It's the third busiest airport in Spain, only surpassed by Madrid-Barajas and El Prat-Barcelona. Summer is the busiest period and it is operational throughout the year.

Over 70 airlines operate in the airport and provide flights connecting to the mainland and the main European capital cities. Furthermore, several airlines have made Palma their hub.

## By sea

Mallorca has two ports for passenger traffic, the Port of Palma, which is the main port on the island, and the Port of Alcúdia. Ideal for those who want to travel to the island with their own car. In addition, many cruises choose the port of Palma as a fixed visit in their tours due to the incomparable beauty of the Bay of Palma.

There are ferry companies in Mallorca that have links to the island from Barcelona, Valencia, Alicante and Denia. These have daily connections that link Mallorca with the aforementioned cities of the Peninsula. The duration of the ferry ride is about 8 hours from Barcelona and, depending on the time of the trip, you can sleep on the boat reserving a cabin.



## Public transportation from the airport to downtown Palma

The Tourist Information Centre is located in the Arrivals terminal. Arrivals are located in the lower floor of the Airport. Rental cars are parked on this floor.

There is parking and toilets for disabled people on all floors.

The airport provides an assistance service for people with reduced mobility, both in Departures and Arrivals. The taxi rank and the main tourist pick-up point for tour operators are located outside the terminal. The airport is excellently connected with Palma via the Ma-19 motorway.

The A1 bus leaves the airport direction Palma centre every 12 minutes. The A2 bus is connecting Airport and s'Arenal every 30 minutes.

# Useful information

## Climate

Palma has an ideal climate thanks to its location, with an average annual temperature of 18 °C.

Temperatures during the month of May are usually in the high 20-24°C range. The minimum temperatures are not usually very low and range from 12-15°C. May is a month in which it does not usually rain a lot.

## Electricity

Voltage: 220/380 volts at a frequency of 50 Hertz. All sockets follow European standards.

To use American-type plugs, a 220-volt transformer should be used together with an adapter plug.

## Currency

The euro is the official currency in Mallorca, the same as the other EU member states who are part of the Monetary Union.

## VAT

The VAT (IVA) or Value Added Tax (*Impuesto sobre el Valor Añadido*) is applied on all products and services.

Citizens of non-EU member countries visiting the island may request the refund of the VAT for purchases exceeding 60.10 Euros (tax-free). In order to request the VAT refund, you must show the invoice of the purchased good at the customs export department of the last European Union member country you will be visiting.





## Two official languages

Mallorca, as well as the other Balearic Islands, has two official languages: Catalan, the island's language, and Spanish, the official language of Spain.

However, it is very common to be served or find restaurant menus in several languages due to the great number of tourists visiting Mallorca.



# Venue information



Auditorium of the Palma de Mallorca  
Av. de Gabriel Roca, 18, Ponent  
07014 Palma  
Illes Balears

The XXXIV Club Jules Gonin Meeting will be held from Wednesday May 22<sup>nd</sup> to Saturday, May 25<sup>th</sup>, 2024, in the Auditorium of the Palma de Mallorca.

# Registration

Registration for the meeting is available through the website [www.mallorca.clubjulesgonin.es](http://www.mallorca.clubjulesgonin.es)

## Mallorca 2024 Registration Fees

GENERAL REGISTRATION	Until 26 <sup>th</sup> January 2024	From 27 <sup>th</sup> January 2024
Member	810 €	900 €
Candidate	880 €	940 €
Guest	880 €	940 €
Accompanying adult	205 €	260 €
Accompanying child <sup>1</sup>	95 €	140 €

### Includes:

- Participation in the scientific sessions.
- Conference folder and programme.
- Free internet access.
- Coffee Breaks.
- Lunches on Thursday 23<sup>rd</sup> and Friday 24<sup>th</sup> May.
- Networking reception – Wednesday 22<sup>nd</sup> May.

### Includes:

- Name bag
- Networking reception – Wednesday 22<sup>nd</sup> May.

VAT 21% included in all fees.

<sup>(1)</sup> Child Registration refers to children from 4 to 16 years old.

Welcome Reception is included in the registration fee.

NETWORKING SESSIONS & DINNER	
Adult	125 €
Child	60 €

CONFERENCE DINNER	
Adult	125 €
Child	55 €

VAT 21% included in all fees.

## Payment method

### Bank transfer:

To the name of DATA EVENTS SERVICES S.L. IBAN account ES82/0182/4651/9502/0154/4006 SWIFT BBVAESMMXXX. A copy of the transfer should be sent together with the registration form. **Please do not send transfers after 13<sup>th</sup> May 2024, as there is a risk that they will not be received before the congress.**

### Credit card:

Only VISA and MasterCard are accepted.



## Cancellation policy

They must be requested via email. All refunds will be made after the meeting. The following rules shall apply: Registrations Cancelled until 22nd April 2024 will be refunded minus a €35 administrative fee.

Registrations Cancelled from 23rd April 2024 onwards will not be eligible for refund.

# Opening Times

There will be a commercial exhibition accompanying our Meeting in Palma de Mallorca this year. The exhibition will be open during the Meeting from 08:30 am on Thursday 23<sup>rd</sup> May.



## Exhibition Opening Time

Thursday 23 <sup>rd</sup> May	08:30 - 14:30
Friday 24 <sup>th</sup> May	08:30 - 18:15
Saturday 25 <sup>th</sup> May	08:30 - 12:00

## Speaker Ready Desk Opening Times

Wednesday 22 <sup>nd</sup> May	12:00 - 18:00
Thursday 23 <sup>rd</sup> May	07:00 - 14:30
Friday 24 <sup>th</sup> May	07:00 - 18:15
Saturday 25 <sup>th</sup> May	07:30 - 12:00

## Registration Desk

The Registration Desk in the Auditorium will be open during these times:

Wednesday 22 <sup>nd</sup> May	12:00 - 18:00
Thursday 23 <sup>rd</sup> May	07:00 - 14:30
Friday 24 <sup>th</sup> May	07:00 - 18:15
Saturday 25 <sup>th</sup> May	07:30 - 12:00

# Scientific Information

---

## Speaker Ready Desk

The Speaker Ready Desk is located close to the Registration Desk. Please follow the signposts. Both PC and Apple Macintosh computers will be available for speakers to check their PowerPoint or keynote presentations prior to their presentation. Presentations should be submitted to the Speaker Ready Desk at least 2 hours before the start of the session. Only Windows (PC) will be available. We can have one Apple computer to convert Keynotes to .pptx on site for those who use Keynote.

The speaker ready desk will be open from 12 noon on Wednesday 22<sup>nd</sup> May.

## Time Allocations for Oral Presentations

Please note that the times allocated for the different types of presentations are the following:

- All oral presentations have been scheduled as a 5-minute presentation with 2 minutes of discussion.

## Poster Presentations

Posters should be placed on panels in the exhibition area on Wednesday 22<sup>nd</sup> May. The Poster Session with refreshments will be held within the poster area on Friday 24<sup>th</sup> May. Poster authors should be present in person during the whole session to discuss their work.

- The title, authors and affiliations should be included in the poster.
- Your poster size is to be 118.9 cm (height) x width 84.1 cm, portrait A0.
- Materials to display your poster on the panel will be provided on site.

# Audiovisual Requirements

---

## Technical Recommendations

The conference room will be equipped with PC/Mac and all presentations will be centralized on the protected server of Auditorium located in the Speaker Ready Desk.

## Procedure during the meeting

After having received your badge, we kindly ask you to proceed to the Speaker Preview Desk where you will receive some assistance. You will be able to check and if necessary, amend your presentation(s).

It will be then sent directly to the laptop PC present at the tech table next to the stage. At the lectern you will have a preview screen and a mouse to control your presentation. Please note there won't be any possibility to upload your presentation directly on the laptop used for your lecture as direct connection from your own laptop at the lectern will not be possible. For organization purposes, we ask you to present yourself at the Speaker Ready Desk the day before your presentation or at least 3 hours before the beginning of your sessions.

## Format of your presentation

Only .pptx is allowed, no.ppt or Apple Keynote presentations. Keynote presentations will be converted to .pptx in the Speaker Ready room.

Please setup your presentation in 16:9 format

PowerPoint -> DESIGN -> Slide size -> Widescreen (16:9)

If you are using PowerPoint 2007 or older versions do not forget to also attach your video files, as they cannot be embedded into the presentation.

## Recommendations

We strongly recommend you to always bring a backup copy of your presentation on USB memory stick.



# Synopsis Scientific Programme

WEDNESDAY 22 MAY	THURSDAY 23 MAY	FRIDAY 24 MAY	SATURDAY 25 MAY
	07:00 Registration Open	07:00 Registration Open	
	08:00 Opening of Meeting	07:30 - 08:15 Gonin Business Meeting	07:30 Registration Open
	08:00 - 09:40 SESSION I Age Related Macular Degeneration	08:15 - 09:25 SESSION VI Diabetic Retinopathy and Vascular Diseases	08:00 - 09:25 SESSION XII Pediatric Retina Dystrophies - Inflammation
	09:40 - 10:15 Break	09:25 - 10:15 Award Session Hermann Wacker Lecture & Jules Gonin Lecture	09:25 - 10:20 Award Session Yasuo Tano Lecture, Mike Trese Award, Gragoudas Award
	10:15 - 11:35 SESSION II Retinal Imaging / Diabetic Retinopathy	10:15 - 11:15 SESSION VII Poster Session VR Surgery and Pediatrics / Dystrophy / Inflammation	10:20 - 10:40 Break
12:00 Registration Open	11:35 - 12:25 SESSION III Vitreoretinal Surgery	11:15 - 12:40 SESSION VIII Vitreoretinal Surgery	10:40 - 12:25 SESSION XIII Clinical and Experimental Studies
	12:25 - 13:00 Lunch	12:40 - 13:45 Lunch	12:25 Adjourn, End of Meeting
	13:00 - 14:00 SESSION IV Vitreoretinal Surgery	13:45 - 15:20 SESSION IX Vitreoretinal Surgery	
	14:00 - 14:30 Break	15:20 - 15:45 Break	
	14:30 - 16:30 SESSION V POSTER SESSION Tumors, Experimental Studies	15:45 - 16:55 SESSION X 30 Tumors	
16:00 - 18:00 Gonin Case Conference	16:00 Networking Session Networking Dinner 16:30	16:55 - 18:15 SESSION XI Poster Session AMD, Retinal Imaging, Diabetic Retinopathy and Vascular Diseases	
		19:15 Conference Dinner	
19:00 - 21:00 Networking Reception			



# Preliminary Scientific Programme

## Wednesday, 22 May 2024

16:00-18:00

### GONIN CASE CONFERENCE

Presenters: F. Arevalo, C.K. Chan, R. Ehrlich, K. El Matri, C. Flaxel, P.H. Gabrielle, A. Mavi Yildiz, W.F. Mieler, R. Muni, Q.D. Nguyen, L. Sandri, L. Vajzovic, L. Wu, L. Yannuzzi

19:00-21:00

### NETWORKING RECEPTION

## Thursday, 23 May 2024

08:00

### OPENING OF MEETING

08:00-09:40

### SESSION I

#### AGE RELATED MACULAR DEGENERATION

- 1 QUANTITATIVE CONTRAST SENSITIVITY CORRELATES BETTER THAN VISUAL ACUITY WITH GEOGRAPHIC ATROPHY SIZE: A NEW FUNCTIONAL ENDPOINT  
J.W. Miller, F. Vingopoulos, M. Stevanovic, P. Razavi, J. Tracy, H. Choi, H. Wescott, G. Baldwin, D. Husain, L.A. Kim, D.G. Vavvas, J.B. Miller
- 2 PATHWAYS TO GEOGRAPHIC ATROPHY IN NON-NEOVASCULAR AGE-RELATED MACULAR DEGENERATION  
R.F. Spaide
- 3 FOVEAL INVASION ANALYSIS OF EYES ENROLLED IN THE GATHER 1 AND 2 PHASE 3 GEOGRAPHIC ATROPHY STUDIES  
G.J. Jaffe, Z.Z. Zemborain, S. Farsiou
- 4 CLINICAL CHARACTERISTICS AND PROGRESSION OF PACHYCHOROID AND CONVENTIONAL GEOGRAPHIC ATROPHY  
A. Tsujikawa, Y. Sato, N. Ueda-Arakawa, A. Takahashi, M. Miyake, Y. Mori, Y. Miyara, C. Hara, Y. Kitajima, R. Maruko, M. Kawai, H. Takahashi, H. Koizumi, R. Kawasaki, M. Maruyama-Inoue, Y. Yanagi, T. Iida, K. Takahashi, T. Sakamoto
- 5 LONG-TERM EFFICACY AND SAFETY OF PEGCETACOPLAN OVER 36 MONTHS: RESULTS FROM 12 MONTHS OF THE GALE OPEN-LABEL EXTENSION STUDY  
J.F. Korobelnik on behalf of the OAKS, DERBY, and GALE study investigators
- 6 NOVEL SIALIC ACID-COATED NANOPARTICLE AVD-104 MODULATES MACROPHAGES AND COMPLEMENT DYSFUNCTION IN NONEXUDATIVE AMD  
T.S. Hassan

- 7 FUNCTIONAL OUTCOME OF THE PRIMA SYSTEM IN PATIENTS WITH GEOGRAPHIC ATROPHY DUE TO AGE-RELATED MACULAR DEGENERATION  
F.G. Holz, Y. Le Mer, M.M.K. Muqit, S. Schmitz-Valckenberg, L. Olmos de Koo, R. Hornig, J. Sahel, for the PRIMAvera Study Group
- 8 BIOENGINEERED STEM CELL DERIVED RPE IMPLANT IN GEOGRAPHIC ATROPHY  
M.S. Humayun, A.H. Kashani, J.S. Lebkowski, D.R. Hinton, B.O. Pennington, N. Rao, L.V. Johnson, D.O. Clegg
- 9 SPATIALLY RESOLVED ASSOCIATION OF STRUCTURAL BIOMARKERS ON RETINAL FUNCTION IN INTERMEDIATE AGE-RELATED MACULAR DEGENERATION OVER SEVEN YEARS  
T. Ach, S. Döngelci, M. Vaisband, L. von der Emde, K.R. Sloan, J. Hasenauer, F.G. Holz, S. Schmitz-Valckenberg, M. Saßmannshausen
- 10 NEXT GENERATION ANTI-VEGF AGENTS - IS TWELVE WEEKS THE NEW NORM?  
D.M. Brown
- 11 FARICIMAB EXTENDED DOSING IN THE PHASE 3 YOSEMITE/RHINE AND TENAYA/LUCERNE TRIALS  
A.H.C. Koh, M. Amador, L. Hill, S. Patel, D. Sim, K. Gibson, P. Margaron
- 12 OUTCOME OF PIGMENT EPITHELIAL DETACHMENTS WITH FARICIMAB VS AFLIBERCEPT TREATMENT DURING HEAD-TO-HEAD DOSING IN PATIENTS WITH NAMD  
N. Eter, P. Margaron, A. Souverain, M. Yang, J.R. Willis, S. Patel, A.M. Khanani, S.J. Bakri, J.I. Lim
- 13 HOME OCT GUIDED MANAGEMENT OF NEOVASCULAR AMD PATIENTS  
A. Loewenstein
- 14 RACIAL AND ETHNIC DISTRIBUTION TRENDS IN AGE-RELATED MACULAR DEGENERATION CLINICAL TRIALS IN THE UNITED STATES IN LAST TWO DECADES  
J. Chhablani, M. Masalkhi, A.J. Yu, E. Waisberg, B. Chen

09:40-10:15

### BREAK

10:15-11:35

### SESSION II

#### RETINAL IMAGING / DIABETIC RETINOPATHY

- 15 A NEW FRAMEWORK ENTAILING STANDARDIZED NOMENCLATURE FOR OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY (OCTA)  
M.R. Munk, L. Faes, F. Turgut, D. Jaggi, B. Freund, V. Sadda, J. Sun, T. Peto, R. Wang, M. Pircher, C. Curcio, A. Kashani
- 16 RETICAD: A TOOL FOR GENERATING DYE-FREE FLUORESCIN ANGIOGRAPHY AND QUANTIFYING RETINAL DISEASE ACTIVITY  
C. Munn, L. Kamintsky, Y. Serlin, J. Levy, O. Tomkins-Netzer, A. Friedman, A. Cruess

# Preliminary Scientific Programme

- 17** ARTIFICIAL INTELLIGENCE FOR PREDICTING THE DEVELOPMENT AND RESULTING VISUAL IMPAIRMENT IN EPIRETINAL MEMBRANE  
Y.T. Hsieh
- 18** AUTOMATED RETINAL VESSEL PARAMETER MEASUREMENTS IN CARDIOLOGIC PATIENTS COMPARED TO HEALTHY CONTROLS  
S. Zweifel, D. Muth, P. Valmaggia, P. Maloca, I. Moarof
- 19** DYNAMIC REDISTRIBUTION OF PIGMENT MOTTILING DURING PROGRESSION OF GEOGRAPHIC ATROPHY; A MULTIMODAL, LONG-TERM TIME-LAPSE ANALYSIS  
M. Paques, M. Darche, Y. Borella
- 20** REAL-TIME DIAGNOSIS OF DIABETIC RETINOPATHY BY A HANDHELD RETINAL CAMERA, ARTIFICIAL INTELLIGENCE AND SIMULTANEOUS SPECIALIST CONFIRMATION IN A REAL-WORLD SETTING  
G.B. Melo, L.F. Nakayama, V.S. Cardoso, L.V.A. Santos, F.K. Malerbi
- 21** AI-BASED BIOMARKER ANALYSIS FOR CENTRAL SEROUS CHORIORETINOPATHY (CSCR)  
J. Roider, M. Santarossa, A. Scharf, R. Koch, H. Handels, T. Kepp, C. von der Burchard
- 22** CHOROIDAL MORPHOLOGY IN CENTRAL SEROUS CHORIORETINOPATHY BY ULTRA-WIDEFIELD OPTICAL COHERENCE TOMOGRAPHY  
T. Iida, I. Maruko, R. Maruko, T. Kawano, M. Sakaiharu, A. Kubota, M. Akiba
- 23** INTRAVITREAL ANTIANGIOGENIC THERAPY FOR PROLIFERATIVE DIABETIC RETINOPATHY: RESULTS FROM THE PAN-AMERICAN COLLABORATIVE RETINA STUDY GROUP (PACORES) AT 24 MONTHS OF FOLLOW-UP  
J.F. Arevalo, A.F. Lasave, L. Wu, A. Alezzandrini, J. Romero, M. Brito, D. Martinez, C. Cordoba, J.D. Arias, R. Silva, N. Gouveia, G. Hüning, A. Pecaku, I. Martins-Melo, R. Shor, P. Oquendo-Aponte, R.H. Muni, M. Maia, S. Rojas
- 24** ONE-YEAR OUTCOMES OF PROACTIVE VERSUS REACTIVE DOSING OF VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS FOR DIABETIC MACULAR EDEMA  
P.H. Gabrielle, H. Mehta, G.D. Kibret, J. Arnold, T. Guillaumie, W.J. Kheir, G. Kok, S. Vujosevic, L. O'Toole, E. Manhelschots, C. Creuzot-Garcher, D. Barthelmes, M. Gillies, for the Fight Retinal Blindness! Study Group
- 25** SEVERAL COMMON VARIATIONS IN GENETIC PROFILE PREDICT EFFECTS OF ANTI-VEGF TREATMENT IN MACULAR EDEMA IN RETINAL CONDITIONS  
R.O. Schlingemann, M.J.C. Vader, K. Aissa, M.W.T. Tanck, I. Klaassen, for the BRAMD, BRVO and BRDME Study Groups

11:35-12:25

## SESSION III

### VITREO-RETINAL SURGERY

- 26** INCREASE IN RETINAL DETACHMENTS - A GLOBAL STUDY.  
S. Binder, A. Roshanshad, Z. Rahimian

- 27** EYE\_CHOOSER: COMPARING THE COST-EFFECTIVENESS, BARRIERS & FACILITATORS TO THE ADOPTION OF ALTERNATIVE SURGICAL TECHNIQUES FOR THE MANAGEMENT OF RETINAL DETACHMENT (RRD) IN THE NATIONAL HEALTH SERVICE  
R.J. Hillier
- 28** PREDICTION OF POSTOPERATIVE VISUAL ACUITY RESTORATION IN MACULA OFF RHEGMATOGENOUS RETINAL DETACHMENT EYES USING ARTIFICIAL INTELLIGENCE  
S. Rizzo, M.C. Savastano, E. Crincoli, R. Kilian, C. Rizzo, A. Savastano
- 29** OPTIMISING VISION IMPROVEMENT AFTER SUCCESSFUL REPAIR OF MACULA OFF RETINAL DETACHMENT  
D. Yorston, P. Donachie, D. Steel, D.A. Laidlaw, T. Williamson
- 30** MACULAR STRUCTURE AND FUNCTION IN PVR RELATED RETINAL DETACHMENT  
R. Anguita, P.Y. Sim, L. Ferro-Desideri, P. Banerjee, M.S. Zinkernagel, D.G. Charteris
- 31** DISTORTION FOLLOWING VITRECTOMY FOR MACULA-ON RHEGMATOGENOUS RETINAL DETACHMENTS  
M. Kamei, Y. Ishida, K. Tsuboi
- 32** PREOPERATIVE BILATERAL EYE PATCHING MAY IMPROVE ANATOMY AND VISUAL OUTCOMES FOR ACUTE PRIMARY RHEGMATOGENOUS RETINAL DETACHMENT  
P.H. Tang, E.H. Ryan

12:25-13:00

## LUNCH

13:00-14:00

## SESSION IV

### VITREO-RETINAL SURGERY

- 33** HYDROGEL-BASED VITREOUS SUBSTITUTES - A NEW CLASS OF TAMPONADES IN RETINAL SURGERY  
P. Szurman
- 34** HEAVY SILICONE OIL IN COMPLEX PRIMARY RETINAL DETACHMENT: A LARGE MULTICENTER MATCHED COHORT STUDY  
D.H. Steel, N. Tzoumas, D. Yorston, D.A. Laidlaw, T.H. Williamson, and the BEAVRS and EURETINA VR Retinal Detachment Outcomes Group
- 35** INTRAOCULAR EMULSION OF SILICONE OIL: CLINICAL VALIDATION OF THE GRADING SYSTEM  
M.R. Romano, M. Ferrara, R.M. Coco-Martin, A. Rickmann, M.S. Spitzer, D.H.W. Steel, J.C. Pastor, ITEMS Study Group
- 36** 25-GAUGE VITRECTOMY AND INCOMPLETE DRAINAGE OF SUB-RETINAL FLUID FOR THE TREATMENT OF PRIMARY RHEGMATOGENOUS RETINAL DETACHMENT  
S. Gotzaridis, P. Petrou, K. Ananikas



# Preliminary Scientific Programme

**37** MANAGEMENT OF PRIMARY RHEGMATOGENOUS RETINAL DETACHMENT WITH PNEUMATIC RETINOPEXY: EXPANDING THE INDICATIONS FROM SINGLE BREAK TO EXTREME CASES WITH GIANT RETINAL TEARS USING THE TORONTO TECHNIQUE

R.H. Muni, M. Cruz Pimentel, I.M. Melo, R.J. Hillier, A. Pecaku

**38** EVALUATION OF INTRAVITREAL METHOTREXATE AS ADJUVANT TREATMENT IN PATIENTS WITH PROLIFERATIVE VITREORETINOPATHY: A RETROSPECTIVE ANALYSIS

L. Vajzovic, A.S. Li, A. Ponugoti, X. Chen, D.S. Grewal, D. Borkar, S. Fekrat, G.J. Jaffe

**39** RHO-KINASE EXPRESSION IN PROLIFERATIVE VITREORETINOPATHY

M. Zinkernagel, R. Anguita, J. Unterlauff, Y. Li, L. Jahnke, V. Enzmann, S. Zandi

**40** PROLIFERATIVE VITREORETINOPATHY: A REVISED CONCEPT OF RETINAL INJURY AND RESPONSE

A. Assi, D. Charteris

14:00-14:30

**BREAK**

14:30-16:30

**SESSION V**

**POSTER SESSION**

**Tumors, Experimental Studies**

**Tumors**

**P1** ENDOLASER DESTRUCTION OF THE FEEDING VESSELS IN LARGE PERIPHERAL RETINAL CAPILLARY HEMANGIOBLASTOMA, IN CASES IN WHICH CONVENTIONAL TREATMENT WAS NOT SUCCESSFUL

E. Rosendi, M. Saravia

**P2** PROGNOSTIC PROTEOMIC FINDINGS IN THE AQUEOUS HUMOR OF EYES AFFECTED BY UVEAL MELANOMA: GNAQ, BAP1, SF3B1 AND EIF1AX

R. Parrozzani, G. Midena, G. Esposito, A. Micera, E. Midena

**P3** GENERATION OF MONOSOMY-3 IN THE UVEAL MELANOMA CELLS IN RESPONSE TO HYPERGLYCEMIA

A. Tura, S. Grisanti

**P4** ASSOCIATION BETWEEN VISUAL FIELD DEFECTS AND BLOOD VESSEL NETWORK FORMATION IN OPTIC DISC MELANOCYTOMA USING OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY

C.S. Lee, J.J. Kwak

**Experimental Studies**

**P5** THE PLACEBO EFFECT IN CENTRAL SEROUS CHORIORETINOPATHY

Y. Subhi, H.C. Kiilgaard, A. Vangsted, J. Bjerager, E.H.C. van Dijk, H.M.A. Feenstra, O.N. Klefter, C.J.F. Boon, J. Grauslund

**P6** MINIATURIZED UP-SCALED, AND HUMANIZED RETINA ORGAN CULTURE AS AN EFFECTIVE EX VIVO MODEL IN INTRAOCULAR DRUG DEVELOPMENT

G. Thumann, T. Bascuas, N. Harmening, M. Mohit, X. Zhu, S. van Delden, A. Conti, M. Kropp

**P7** OPHTHALMIC ARTERY ANGIOPLASTY FOR GEOGRAPHIC ATROPHY: RATIONALE AND PERSPECTIVE, PILOT STUDY

M. Saravia, J. Rojas, F. Forgues, P. Bazterrechea, I. Lylyck, C. Bleise, P. Lylyck

**P8** DE NOVO PIGMENTATION OF AMELANOTIC RETINAL PIGMENT EPITHELIAL CELLS

G. Petrovski

16:30

**NETWORKING SESSION**

**NETWORKING DINNER**

**Friday, 24 May 2024**

07:30-08:15

**GONIN BUSINESS MEETING**

08:15-09:25

**SESSION VI**

**DIABETIC RETINOPATHY AND VASCULAR DISEASES**

**41** EFFICACY AND SAFETY FINDINGS FROM DIAMOND: A PHASE 2/3 DOUBLE-MASKED, RANDOMIZED, MULTICENTER STUDY OF OCS-01 OPTIREACHR® TECHNOLOGY TOPICAL DEXAMETHASONE EYE DROPS IN SUBJECTS WITH DME

Q.D. Nguyen for the OCS-01 DME DIAMOND Study Group

**42** AFLIBERCEPT 8 MG FOR DIABETIC MACULAR EDEMA: 96-WEEK RESULTS FROM THE PHASE 2/3 PHOTON TRIAL

D.V. Do on behalf of the PHOTON study investigators

**43** FARICIMAB REDUCES MACULAR LEAKAGE VS AFLIBERCEPT IN PATIENTS WITH DME

S. Bressler, E. Nudleman, R. Goldberg, K. Csaky, A.M. Kolomeyer, K. Gibson, F. Mar, T. Wang, J.R. Willis

**44** LIQUID BIOPSY FOR PROLIFERATIVE DIABETIC RETINOPATHY: SINGLE-CELL TRANSCRIPTOMICS (SCRNA-SEQ) REVEALS INFLAMMATORY T CELL SIGNATURE IN THE DIABETIC HUMAN VITREOUS

R.C. Rao, R. Haliyur, D.A. Parkinson, J. Xu, Q. Li, Y. Huang, J. Liu, F. Ma, J.E. Gudjonsson

**45** EVALUATING THE RELATIONSHIP BETWEEN BEST-CORRECTED VISUAL ACUITY (BCVA) AND MEASURES OF HEALTH AND VISUAL-RELATED QUALITY OF LIFE (QOL) IN PEOPLE WITH DIABETIC MACULAR OEDEMA (DMO)

N. Lois, R. Khan, I. Khan, for the DIAMONDS Study Group

# Preliminary Scientific Programme

**46** CHOROIDAL THICKNESS CHANGES IN DIABETIC PATIENTS  
J. Potic, J. Baffou, A. Milloz, M. Tomasoni, I. Meloni, S. Mousavi, A. Elwakil, R. Schlingemann, L. Konstantinidis, C. Bergin, T.J. Wolfensberger

**47** BIOMARKERS FOR VASCULAR STABILITY, INCLUDING INFLAMMATION, AND FIBROSIS, DEMONSTRATE THE BENEFIT OF DUAL ANG-2/VEGF-A INHIBITION WITH FARICIMAB IN PHASE 3 TRIALS IN DME

J.A. Wells, A. Maunz, K. Patel, E. von Schulthess, T. Wang, J.R. Willis, K. Gibson

**48** LONGITUDINAL ASSESSMENT OF INTRARETINAL MICROVASCULAR ABNORMALITIES IN DIABETIC RETINOPATHY USING WIDE FIELD SWEEP SOURCE OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY

J.B. Miller, X. Ding, F. Romano, I. Garg, J. Gan, K.M. Overbey, M.D. Garcia, F. Vingopoulos, Y. Cui, Y. Zhu, I. Lains, E.S. Lu, G. Baldwin, J.H. Tracy, H. Choi, J.M. Rodriguez, M.J. Finn, P. Razavi, N.A. Patel, L.A. Kim, J.W. Miller, D.G. Vavvas, D. Husain

**49** THE SPECTRUM OF DIABETIC MACULAR EDEMA: COMBINING OMIC AND IMAGING APPROACH

E. Midena, L. Frizziero, L. Danieli, M. Bruno, A. Micera, M. Cecere, G. Midena

**50** DEEP LEARNING FOR DIABETIC RETINOPATHY SCREENING USING STANDARD AND PORTABLE FUNDUS CAMERAS FOR PRIMARY CARE PHYSICIANS

T.Y. Wong, J. Li, Z. Guan, Y.C. Tham, B. Sheng on behalf of DeepEYE Consortium

09:25-10:15

## AWARD SESSION

**HERMANN WACKER LECTURE: EMILY CHEW**

**JULES GONIN LECTURE: ANAT LOEWENSTEIN**

10:15-11:15

## SESSION VII

### POSTER SESSION

#### VR Surgery and Pediatrics/Dystrophy/ Inflammation

##### Vitreoretinal Surgery

**P9** CURRENT ROLE OF PNEUMATIC RETINOPEXY IN THE PRIMARY REPAIR OF RHEGMATOGENOUS RETINAL DETACHMENT

T.C. Verstraeten, T.R. Friberg

**P10** RISK OF RETINAL DETACHMENT IN RELATION TO AXIAL LENGTH – A DANISH REGISTRY STUDY FROM 2000 TO 2021

D.M. Leegaard Holm, B.R. Nielsen, M. Alberti, T.G. Krarup, M.B. Knudsen, T. Martinussen, M. la Cour

**P11** DAY-1 POST-OPERATIVE FOLLOW-UP IN VR SURGERY: IS IT ALWAYS NECESSARY AFTER UNEVENTFUL PROCEDURES?

F.M. D'Alterio, N. Hakim, Liverpool VR group, C. Groenewald, T. Sandinha

**P12** THE IMPACT OF DRAINAGE RETINOTOMY ON ANATOMICAL AND FUNCTIONAL OUTCOMES OF PARS PLANA VITRECTOMY FOR PRIMARY RHEGMATOGENOUS RETINAL DETACHMENT

M. Ferrara, G. Moussa, N. Tzoumas, T. Ivanova, D. Yorston, A. Jalil, D. Steel

**P13** LONG-TERM VISUAL ACUITY IN UNCOMPLICATED RHEGMATOGENOUS RETINAL DETACHMENT: FACTORS IMPLICATING RISK OF LOW VISION?

P. Mammadzada, S. Crafoord

**P14** MINIMAL, NON-DRAINAGE BUCKLING IN THE AGE OF VITRECTOMY

M. Engelbert, R. Gupta, T. Kaden, W. Schiff, G. Barile

**P15** RETINA SWELLING, INTRARETINAL FLUID AND FOVEAL ILM DEPOSITIONS FOLLOWING PARS PLANA VITRECTOMY WITH SILICONE OIL ENDOTAMPONADE

A. Weinberger, P. Raak, H. Gerding

**P16** LONG TERM RESULTS FROM THE VIPER TRIAL - REPAIR OF UNCOMPLICATED PSEUDOPHAKIC RETINAL DETACHMENT USING VITRECTOMY WITH OR WITHOUT ENCIRCLING BAND

P. Walter, S. Baumgarten, M. Hellmich, P. Schiller, and the VIPER Study Group

**P17** RHEGMATOGENOUS RETINAL DETACHMENTS MASQUERADING AS SEROUS RETINAL DETACHMENTS

C. Flaxel, Z. Kroeger

**P18** EVALUATION OF MICROSCOPE-INTEGRATED OCT IMAGING PERFORMANCE IN BYEONICS ONE EXOSCOPE

A. Barak

**P19** MONITORING LOCAL RETINAL FUNCTION DURING VITREOUS SURGERY BY INTRAOPERATIVE FOCAL MACULAR ELECTRORETINOGRAM

K. Shinoda, S. Matsumoto, Y. Miyake, M. Inoue, A. Hiraakata

**P20** QUANTITATIVE EVALUATION OF VITREOUS FORCEPS CHARACTERISTICS AND THEIR EFFECT ON THE RETINAL SURFACE

T. Koto, A. Hiraakata, M. Inoue

**P21** MACROPHAGE-MYOFIBROBLAST TRANSITION CONTRIBUTES TO MYOFIBROBLAST FORMATION IN PROLIFERATIVE VITREORETINAL DISORDERS

A.M. Abu El-Asrar, G. De Hertogh, E. Allegaert, M.I. Nawaz, S. Abouelasrar Salama, P.W. Gikandi, G. Opendakker, S. Struyf

**P22** TRANSCRIPTOMIC ANALYSIS OF POSTERIOR VITREOUS DETACHMENT ASSOCIATED WITH VITREOMACULAR PATHOLOGY

M.P. Snead, M. Meranian, T.R.W. Nixon, E.C. Rodriguez, H. Martin

**P23** LARGE AMNIOTIC MEMBRANE GRAFT ASSISTED BY SUB-PERFLUOROCARBON LIQUID VISCOAT INJECTION FOR RECURRENT MYOPIC MACULAR HOLE

C.C. Lai, E.Y.C. Kang, H.D. Chou, L.H. Chuang, W.C. Wu

**P24** PLASMA-RICH GROWTH FACTORS (PRGF) FOR THE TREATMENT OF PERSISTENT MACULAR HOLES

A. Alezandri, A.L. Carauni, M. Pestalardo, P. Chamartin

# Preliminary Scientific Programme

**P25** THE EFFECT OF FACE DOWN POSITIONING IN MACULAR HOLE SURGERY: AN INDIVIDUAL PARTICIPANT DATA STUDY OF RANDOMIZED CONTROLLED TRIALS

R. Raimondi, N. Tzoumas, S. Toh, V. Chaudhary, G. Sarohia, D.H. Steel

**P26** ASSOCIATION OF MICROVASCULATURE CHANGES WITH VISUAL OUTCOMES IN IDIOPATHIC EPIRETINAL MEMBRANE SURGERY

J.P. Berrod, M. Henry, J.B. Conart

**P27** DESCRIBING IDIOPATHIC EPIRETINAL MEMBRANE BY AN EN-FACE APPROACH

F.J. Rodríguez, H.A. Ríos, J. Villa, L. Herrán, S. Meneses, L.A. Daza

**P28** TO REPORT A NOVEL ROTATIONAL INTERNAL LIMITING MEMBRANE (R-ILM) FLAP TECHNIQUE FOR LARGE MACULAR HOLES (MH)

P. Zhao, J. Lyu

**P29** THE TIME COURSE OF SPONTANEOUS CLOSURE OF IDIOPATHIC FULL THICKNESS MACULAR HOLES

F. Gelisken, J. Neubauer, T. Öztürk, K.U. Bartz-Schmidt, S. Dimopoulos

**P30** SHORT-TERM-OUTCOMES OF FULL-THICKNESS MACULAR HOLES TREATED WITH PEELED INTERNAL LIMITING MEMBRANE REPOSITION

B.V. Stanzel, W. Darwisch, D. Weber, K. Savioli, P.K. Roberts, P. Szurman

**P31** RESULTS OF A LARGE SERIES OF MACULAR HOLE SURGERIES WITH LONG-ACTING GAS TAMPONADE AND INTERNAL LIMITING MEMBRANE REMOVAL

J.T. Thompson

**P32** NOVEL TECHNOLOGY TOOLS FOR REMOTE SURGICAL TRAINING

E.B. Rodrigues, F.A. Lucato, L.H. Lima, M.E. Farah

**P33** ENVIRONMENTAL IMPACT OF VITREORETINAL SURGERY AND MEASURES WE CAN TAKE TO REDUCE IT

S. Saidkasimova

## Pediatric Retina and Dystrophies - Inflammation/ Endophthalmitis

**P34** DOMINANT COL9A3 STICKLER SYNDROME

T.R.W. Nixon, H. Martin, A.V. Poulson, P. Alexander, A. McNinch, A.R. Richards, M.P. Snead

**P35** MATRIX METALLOPROTEINASE 2 AS A POTENTIAL THERAPEUTIC TARGET IN CHOROIDEREMIA

A.T. Fahim, M. Raeker, L. Chen, N. Dayanthi Perera, A.J. Karoukis, K.L. Feathers, R.R. Ali, D.A. Thompson

**P36** EVALUATION OF RETINAL FINDINGS IN HARD-CORE COCAINE ADDICTS ENROLLED IN A GENE-THERAPY BASED, PHASE 1, ANTI-COCAINE VACCINE CLINICAL TRIAL

S. Kiss, A. Ruda, S. Hyde, D.J. D'Amico, R.G. Crystal, K. Kovacs

**P37** DIAMETER AND THICKNESS OF WALL OF A RETINAL ARTERIOLE IN EYES WITH RETINITIS PIGMENTOSA DETERMINED BY ADAPTIVE OPTICS IMAGING

S. Ueno, H. Terasaki, J. Ota, T. Inooka, K.M. Nishiguchi, T. Kominami

**P38** EXPLORING THE MOLECULAR INTERSECTION OF TUBERCULAR SERPINGINOUS-LIKE CHOROITIS: MYCOBACTERIUM TUBERCULOSIS PROTEINS, OCULAR AUTOIMMUNITY, AND IMMUNE RECEPTOR INTERACTIONS

I. Kutlutürk Karagöz, M. Kaya, M.R. Munk

**P39** CYTOMEGALOVIRUS RELATED ANTERIOR UVEITIS (CMV-AU) IN A MEDITERRANEAN EUROPEAN POPULATION: CLINICAL FEATURES, PROGNOSIS AND LONG-TERM TREATMENT OUTCOMES

P. Tranos, S. Koronis, N. Markomichelakis, A. Rasoglou, M. Tranou, P. Stavarakas

**P40** COMPARISONS OF CHOROIDAL BLOOD FLOW VELOCITY BETWEEN INITIAL-ONSET ACUTE UVEITIS ASSOCIATED WITH VOGT-KOYANAGI-HARADA DISEASE AND ACUTE CENTRAL SEROUS CHORIORETINOPATHY

M.A. Abouammoh, A.M. Abu El-Asrar, A.F. AlBloushi, A. Alzubaidi, P.W. Gikandi, A. Al Faran, A. Al Kharashi, S. Al Dahmash

**P41** VITRECTOMY SPARING SURGICAL TECHNIQUE TO TREAT ECTOPIA LENTIS IN PEDIATRIC PATIENTS

L. Lytvynchuk, M. Andrassi-Darida, M.J. Tassignon

**P42** TRENDS IN ROP SCREENING AND TREATMENT IN GERMANY OVER 12 YEARS: EFFECTS OF NATIONAL GUIDELINE CHANGES

T.U. Krohne, A.T. Camp, J.M. Pfeil, J.Q. Li, W.A. Lagrèze, A. Stahl, for the EU-ROP Registry Study Group

11:15-12:40

## SESSION VIII

### VITREO-RETINAL SURGERY

**51** VITRECTOMY FOR VISION DEGRADING MYODESOPSIA FROM VITREOUS FLOATERS

J. Sebag, J.H. Nguyen, S.K. Boneva

**52** VITREOUS FLOATERS AND OPACITIES (VFO): REACHING AN OBJECTIVE DECISION OF WHEN AND HOW TO TREAT

P.E. Stanga, A. Saladino, F.J. Valentin Bravo, U. Reinstein, S.E.F. Stanga, J. Marshall, T. Archer, D. Reinstein

**53** LATE INTRAOCULAR LENS DISPLACEMENT: A MULTI-NATIONAL STUDY

A. Chandra, C. Chipeta, J. Zhang

**54** EDOF IOLS AFTER RETINAL DETACHMENT REPAIR: THE EIRE STUDY

A. Wolf

**55** REVERSE PUPILLARY BLOCK AFTER IMPLANTATION OF A SUTURELESS SCLERAL FIXATION (SFF) IOL (CARLEVALE, SOLEKO)

J. G. Arumi, C. Garcia-Arumi Fusté, L. Sanchez Vela, D. Ruiz Casas

# Preliminary Scientific Programme

- 56** NEW CONCEPTS IN THE BENEFITS OF EARLY VITRECTOMY VS. INTRAVITREAL INJECTIONS IN ENDOPTHALMITIS: A 9-YEAR RETROSPECTIVE ANALYSIS AND 3-YEAR PROSPECTIVE RANDOMIZED STUDY  
M. Maia, V.C. Bergamo, L.F. Nakayama, N.S.B. De Moraes, M.E. Farah, A.L. Höfling-Lima
- 57** MATHEMATICAL SIMULATION OF GAS MIX ERRORS IN VITREORETINAL SURGERY  
T.H. Williamson, J.Y. Guillemaut, M. Romano, M. Ferrara
- 58** EFFECT OF INTRAVITREAL BEVACIZUMAB ON THE SEQUELAE OF PROLIFERATIVE VITREORETINOPATHY FOLLOWING POSTERIOR SEGMENT OPEN GLOBE INJURIES: A RANDOMIZED CONTROLLED STUDY  
V.P. Dave, P. Palan
- 59** INTRAOPERATIVE FLUORESCEIN ANGIOGRAPHY (FA) DURING DIGITALLY ASSISTED VITREORETINAL SURGERY (DAVS) FOR RETINOVASCULAR DISEASES- A PILOT STUDY  
M.H. Berrocal, L.A. Acabá-Berrocal
- 60** CANNULATION OF CENTRAL RETINAL ARTERY OCCLUSION ASSISTED WITH ROBOTICS  
K. Kadosono, T. Tanaka, H. Enaida
- 61** COMPARISON OF SURGICAL TIMES BETWEEN MANUAL AND ROBOT-ASSISTED EPIRETINAL MEMBRANE PEELING  
M.D. Becker, A. Eberle, G.M. Somfai, A. Saad, P.W. Hasler, F. Turgut
- 62** RETINAL TANGENTIAL DISPLACEMENT AFTER MACULAR PUCKER SURGERY  
T. Rossi, G. Ripandelli, M. Stirpe
- 67** PROSPECTIVE ASSESSMENT OF AUTOLOGOUS MACULAR TRANSPLANTATION OUTCOMES USING FUNDUS-CONTROLLED MICROPERIMETRY AND OCT ANGIOGRAPHY  
M.S. Singh, T. Patel, J.F. Arevalo, C. Toomey, B. Antonio-Aguirre
- 68** WHY DO SOME HOLES RESIST TO CLOSE- PREDICTIVE FACTORS OF SURGICAL SUCCESS WITH THE INVERTED ILM FLAP TECHNIQUE  
Z.A. Nawrocka, J. Nawrocki
- 69** MANAGEMENT OF LARGE RECALCITRANT FULL THICKNESS MACULAR HOLES: THE LARGO STUDY  
M.T. Sandinha, F.M. D'Alterio, R. Henderson, D. Steel for the BEAVRS LARGO study group
- 70** COMBINED AMNIOTIC MEMBRANE GRAFT AND AUTOLOGOUS RETINAL TRANSPLANT FOR REPAIR OF REFRACTORY CHRONIC MYOPIC MACULAR HOLES WITH UNDERLYING ATROPHY  
T.H. Mahmoud
- 71** MACULAR RETINAL FUNCTION AFTER AUTOLOGOUS RETINAL TRANSPLANT IN PATIENTS WITH REFRACTORY MACULAR HOLES  
H. Terasaki, T. Inoue, S. Ueno, K. Tsunoda, R. Arasaki, K. Kadosono
- 72** A NOVEL SURGICAL TECHNIQUE FOR GIANT AND REFRACTORY MACULAR HOLES: AUTOLOGOUS TENON CAPSULE PLUG  
A. Mavi Yildiz, S. Yilmaz, R. Avci
- 73** PLASMA RICH IN GROWTH FACTORS FOR COMPLEX MACULAR HOLES  
M.S. Figueroa, A. Govetto
- 74** EPIRETINAL TISSUE PRESERVING TEMPORAL INVERTED ILM FLAP TECHNIQUE FOR THE TREATMENT OF LAMELLAR MACULAR HOLES WITH EPIRETINAL PROLIFERATION  
R. Avci, A. Mavi Yildiz, S. Yilmaz
- 75** MACULAR EPIRETINAL MEMBRANES IN EYES THAT UNDERWENT LARGE RETINECTOMIES FOR PVR  
T. Papakostas, S. Dang, A. Durrani, B. Smith, N. Engelbrecht, D. Joseph, G. Shah, K. Blinder

12:40-13:45

## LUNCH

13:45-15:20

## SESSION IX

### VITREO-RETINAL SURGERY

- 63** EVOLUTION OF MYOPIC MACULAR SCHISIS WITH GOOD VISUAL ACUITY AT DIAGNOSIS  
R. Tadayoni, E. Philippakis, A. Seneclauze, A. Couturier
- 64** POSTOPERATIVE ANATOMICAL OUTCOMES OF EPIRETINAL MEMBRANES WITH FOVEOSCHISIS DIFFERIANTE THEM FROM LAMELLAR MACULAR HOLES  
M. Lam, E. Philippakis, A. Gaudric, R. Tadayoni, A. Couturier
- 65** DETAILED CLASSIFICATION OF LAMELLAR MACULAR HOLE AND RELATED DISEASES WITH OCT VOLUME SCAN IMAGING  
Y. Morizane, M. Hosokawa, R. Matoba
- 66** SUBRETINAL HYDRODISSECTION TO CLOSE FULL THICKNESS MACULAR HOLES: A GLOBAL PERSPECTIVE - THE SEAL COLLABORATION -  
C.H. Meyer for the SEAL collaboration

15:20-15:45

## BREAK

15:45-16:55

## SESSION X

### TUMORS

- 76** SMALL UVEAL MELANOMA: LONG TERM 5-YEAR FOLLOW-UP OF MIVS TUMOR ABLATION COUPLED WITH GENE EXPRESSION PROFILING  
T.G. Murray, A. Latiff, A. Gold
- 77** DIAGNOSTIC VALUE OF CIRCULATING TUMOR CELLS IN SMALL CHOROIDAL MELANOCYTIC LESIONS  
S. Grisanti, A. Tura



# Preliminary Scientific Programme

- 78** DETECTION OF TUMOR DNA IN AQUEOUS HUMOR FROM PATIENTS WITH UVEAL MELANOMA  
M. Bagger, C. Dahl, J.J. Dollar, C. Faber, Z. Correa, P. Guldberg, J.W. Harbour, J.F. Kiilgaard
- 79** UVEAL MELANOMA GENE EXPRESSION PROFILE PREDICTION FROM ULTRA-WIDEFIELD FUNDUS PHOTOGRAPHS USING AUTOMATED MACHINE LEARNING  
P. Mruthyunjaya, J.T. Sokol, K. Jaje, H. Ahmad, E. Korot
- 80** DEXAMETHASONE INTRAVITREAL IMPLANT FOR THE MANAGEMENT OF EXUDATIVE RETINAL DETACHMENT IN PATIENTS WITH CHOROIDAL MELANOMA  
I.K. Kim, E.S. Gragoudas, A.M. Lane
- 81** GAMMA KNIFE RADIOSURGERY FOR CHOROIDAL MELANOMA: A RETROSPECTIVE REVIEW OF CLINICAL OUTCOMES IN A SOUTH AFRICAN REFERRAL CENTRE  
L. Sandri, B. Jordaan, K. Kloete, C. Jordaan
- 82** THE METASTATIC PATTERNS OF UVEAL MELANOMA AND THE IMPACT ON SURVIVAL  
J.F. Kiilgaard, T.G. Hindsø, C.W. Bjerrum, E. von Benzon, C. Faber, K. Nissen, S. Heegaard, M. Donia, I.M. Svane, E. Ellebæk, K. Madsen, M. Bagger
- 83** HOW TO MAINTAIN FUNCTION IN EYES AFTER IRRADIATION FOR CHOROIDAL MELANOMA  
A.M. Joussem
- 84** VITREORETINAL TECHNIQUES FOR THE MANAGEMENT OF TUMOUR ASSOCIATED SUB RETINAL HAEMORRHAGE  
R.N. Hussain, H. Heimann
- 85** SURGICAL TREATMENT OF TOTAL EXUDATIVE RETINAL DETACHMENT FOLLOWING PROTON BEAM RADIOTHERAPY FOR UVEAL MELANOMA  
H. Heimann, C. Groenewald, R. Hussain
- P45** ARTIFICIAL SWEETENERS AND NEOVASCULAR AGE-RELATED-MACULAR-DEGENERATION: NOVEL CLINICAL AND EXPERIMENTAL INSIGHTS  
O. Zeitz, S.E. Künzel, I.M. Pompös, L.T.M. Flesch, D.P. Frentzel, V.A. Knecht, S. Skosyrski, A. Rübsam, F. Dreher, N. Kociok, M. Schütte, A. Dubrac, B. Lange, M.L. Yaspo, H. Lehrach, O. Strauß, A.M. Joussem
- P46** INFLAMMATORY PHENOTYPE ASSOCIATED WITH HIGH RISK MMP9 GENOTYPE IN NEOVASCULAR AMD  
E. Sohn, Z. Zacharias, K. Lee, C. Mukhopadhyay, R. Coussa, I. Han, T. Scheetz, J. Fingert, M. Abramoff, E. Stone, J. Houtman, M. Sonka
- P47** MACULAR ATROPHY EVOLUTION IN NAMD EYES COMPARED TO THEIR FELLOW DAMD EYES  
M.K. Tsilimbaris, S. Blazaki, E. Blavakis, G. Bontzos, I. Chatziralli, D.G. Vavvas, G. Smoustopoulos, E. Dimitriou, A. Stavrakakis, S. Kabanarou, T. Xirou, G. Chlouverakis
- P48** METABOLOMIC ENDOTYPES OF AGE-RELATED MACULAR DEGENERATION (AMD) USING MACHINE LEARNING  
D. Husain, K. Mendez, I. Lains, J.B. Miller, D. Vavvas, R. Silva, I.K. Kim, L. Liang, J. Lasky Su, J.W. Miller
- P49** OCT FEATURES OF DISEASE ACTIVITY AFTER INITIAL TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION  
C.S. Tan
- P50** OUTCOMES OF ANTI-VEGF THERAPY FOR WET AGE-RELATED MACULAR DEGENERATION IN PATIENTS AGED 85 AND OLDER  
M. Hosokawa, Y. Morizane
- P51** GEOGRAPHIC ATROPHY - ALWAYS AMD?  
M. Maier, M. Grünwald
- P52** EARLY ONSET AMD, LESSONS TO LEARN  
C.B. Hoyng, A. de Breuk, Y. Lechanteur
- P53** SOFT DRUSEN REGRESSION WITHOUT ATROPHY IN AGE-RELATED MACULAR DEGENERATION: A POORLY UNDERSTOOD PHENOMENON  
J. Monés, F. Pagani
- P54** MNV-REMODELING DURING LONG TERM ANTI-VEGF-THERAPY IN NAMD  
D. Pauleikhoff

16:55-18:15

## SESSION XI

### POSTER SESSION

#### AMD, Retinal Imaging, Diabetic Retinopathy and Vascular Diseases

##### Age Related Macular Degeneration

- P43** CLINICAL MANIFESTATION OF MACULAR NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION AMONG INDIVIDUALS HOMOZYGOUS FOR RISK ALLELES SOLELY ON CHROMOSOME 1 (CFH-CFHR5), SOLELY ON CHROMOSOME 10 (ARMS)  
S. Schmitz-Valckenberg, B. Solinsky, M.A. Zouache, W. Brinkley, C. Pappas, J. Hageman, M. Fleckenstein, G.S. Hageman
- P44** LASER FLARE PHOTOMETRY IN EYES RECEIVING BROLUICIZUMAB INTRAVITREAL INJECTIONS FOR AGE-RELATED MACULAR DEGENERATION  
S. Androudi, N. Chadoulos, A. Dastiridou, A. Mitsios, I. Tsinopoulos, C. Kalogeropoulos

##### Retinal Imaging

- P55** OCCURRENCE AND PROGRESSION OF ATROPHY ASSOCIATED WITH MYOPIC CHOROIDAL NEOVASCULARIZATION  
E. Philippakis, M. Couasnon, A. Couturier, R. Tadayoni
- P56** ANALYSIS OF RETINAL MICROSTRUCTURE AND ELECTROPHYSIOLOGY IN EYES FOLLOWING PARS PLANA VITRECTOMY AND MEMBRANE PEELING FOR VITREOMACULAR INTERFACE DISORDERS  
S.J. Sheu, Y.H. Chen

# Preliminary Scientific Programme

**P57** AUTOMATIC IDENTIFICATION OF PACHYCHOROID ON OPTICAL COHERENCE TOMOGRAPHY, USING DEEP LEARNING

O. Gal-Or, A. Tiosano, D. Finberg, Y. Giladi, I. Perchik, I. Deitch Harel, A. Meshi, N. Gilad, T. Weinberg, R. Ehrlich

**P58** EXPLORING THE FACTORS INFLUENCING RECURRENCE OF CENTRAL SEROUS CHORIORETINOPATHY USING MACHINE LEARNING

C.M. Eandi, E. Seiler, L. Delachaux, M. Tomasoni

**P59** LONG-TERM COMPLICATIONS AND MANAGEMENT OF WEST NILE VIRUS WITH MULTI-MODAL IMAGING

L.J. Faia, T. Begai, Z. Taqueer

**P60** OPTICAL COHERENCE TOMOGRAPHY AS A HIGH DYNAMIC RANGE IMAGING MODALITY IN SUBRETINAL HYPERREFLECTIVE MATERIAL (SHRM)

R. Gallego-Pinazo, S. Montolio-Marzo, R. Dolz-Marco

**P61** TIME-RESOLVED DYNAMIC OPTICAL COHERENCE TOMOGRAPHY FOR RETINAL BLOOD FLOW ANALYSIS

P.M. Maloca, P.C. Cattin, R. Sandkühler, N. Inglin, T.P. Otto, S. Aumann, M.M. Teussink, R.F. Spaide, H.P.N. Scholl, P. Valmaggia

## Diabetic Retinopathy and Vascular Diseases

**P62** OUTCOMES OF RETINAL NEURODEGENERATIVE CHANGES IN PATIENTS WITH DIABETIC MACULAR EDEMA FROM THE VISTA STUDY

D.S. Grewal, on behalf of the VISTA study investigators

**P63** EFFECT OF ORAL LAMIVUDINE VERSUS PLACEBO IN DIABETIC MACULAR EDEMA: A RANDOMIZED CLINICAL TRIAL

F. Pereira, J. Magagnoli, M. Ambati, T.F. Oliveira, J.A.E. Oliveira, V.O. Pesquero, L.Z. Ribeiro, D.A.K. Kuroiwa, F.K. Malerbi, S.A. Dib, N.B. Moraes, M.E. Farah, E.B. Rodrigues, J. Ambati

**P64** THE COST OF BEAUTY: CENTRAL RETINAL ARTERY OCCLUSION AFTER COSMETIC PROCEDURE, A CASE REPORT

N. Camacho, V. Mazorra, H. Camacho

**P65** DOES EXTENSIVE MACULAR ATROPHY WITH PSEUDODRUSEN (EMAP) RELATE TO LATE RETINAL FINDING ON BRAZILIAN PATIENTS WITH PREVIOUSLY RHEUMATIC FEVER?

C.A. Moreira-Neto, R.A.S. Andujar, J.C. Chao, E.C. Souza, A. Maia, F.E.E. Alves, H. Vasconcelos, J.M.F. Sallum, B. Hirt, J. Arana, C.A. Moreira Jr.

**P66** OBSTRUCTIVE SLEEP APNEA AS A RISK FACTOR FOR DIABETIC RETINOPATHY PROGRESSION AND SYSTEMIC COMPLICATIONS

E. Rahimy, P. Mruthyunjaya

**P67** MACHINE LEARNING-BASED PREDICTION OF VITREORETINAL DISORDERS BASED ON VITREOUS CYTOKINE PROFILES

Y. Usui, N. Nezu, R. Sugawara, K. Tsubota, H. Goto

**P68** THE LARGE SPOT 689NM LASER THERAPY WITH FOR PERSISTENT SUBRETINAL FLUID IN PACHYCHOROID SPECTRUM DISEASES

T. Kim, J. Lee, K. Kim, S. Yu

**P69** CHALLENGING THE NOTION OF THE POINT OF NO RETURN IN CRORA

F.S. Pagani, J. Monés, J.F. Santamaria

**P70** ACCURACY OF AUTONOMOUS ARTIFICIAL INTELLIGENCE-BASED DIABETIC RETINOPATHY SCREENING IN REAL LIFE CLINICAL PRACTICE

E. Riotto, S. Gasser, J. Potic, M. Sherif, T. Stappler, R. Schlingemann, T.J. Wolfensberger, L. Konstantinidis

**P71** WEEK 48 OUTCOMES IN AFLIBERCEPT 8 MG- AND 2 MG-TREATED PATIENTS BY PRIOR DME TREATMENT STATUS: A SUBGROUP ANALYSIS OF THE PHASE 2/3 PHOTON TRIAL

A.A. Moshfeghi, on behalf of the PHOTON study investigators

**P72** ASSOCIATION OF RETINAL THICKNESS AT MONTH 1 WITH LATER RETINAL THICKNESS, VISUAL ACUITY, AND NUMBER OF TREATMENTS IN EYES WITH CENTRAL OR HEMI-RETINAL VEIN OCCLUSION ENROLLED IN THE SCORE2 TRIAL

I.U. Scott, N.L. Oden, P.C. VanVeldhuisen, M.S. Ip, B.A. Blodi, for the SCORE2 Investigator Group

**P73** LONGITUDINAL ASSESSMENT OF STRUCTURAL AND MICROVASCULAR CHANGES IN A PEDIATRIC POPULATION WITH TYPE 1 DIABETES

M. Parravano, S. Fragiotta, F. Picconi, P. Giorno, M. Menduni, L. Chioma, E. Costanzo, P.I. Patera, M. Varano

**P74** CORNEAL SENSITIVITY IS INVERSELY CORRELATED WITH SEVERITY OF DIABETIC RETINOPATHY IN A PREDOMINANTLY UNDERREPRESENTED POPULATION

M.A. Singer, P. O'Brien, L. Mein, A. Olivera

19:15

## CONFERENCE DINNER

**Saturday, 25 May 2024**

08:00-09:25

## SESSION XII

### PEDIATRIC RETINA DYSTROPHIES - INFLAMMATION

**86** PROSPECTIVE EVALUATION OF TELEROP SEVERITY SCORING IN ~1% OF USA NICUS

D.M. Moshfeghi

**87** PRETERM INFANT RETINAL NERVE FIBER LAYER THICKNESS FROM OCT IN THE NURSERY: A WINDOW INTO NEURODEVELOPMENT AT AGE 2 YEARS

C.A. Toth, N. Sarin, K.E. Gustafson, J. He, C.M. Cotten, G.S. Ying, BabySTEPS Group

# Preliminary Scientific Programme

- 88** EFFICACY OF A NEW MOBILE NON-CONTACT ULTRA WIDEFIELD IMAGING SYSTEM TO SCREEN FOR RETINOPATHY OF PREMATURITY(ROP)  
C.K. Patel, R. Purohit, A. Ie, S. Aslam, K. Xue
- 89** ADMINISTERING INTRAVITREAL BEVACIZUMAB FOR RETINOPATHY OF PREMATURITY: 8-YEAR COGNITIVE OUTCOMES IN A PROSPECTIVE COHORT  
W.C. Wu
- 90** SLIT-LAMP PATTERN SCAN LASER PHOTOCOAGULATION GUIDED BY ANGIOGRAPHY: A PROMISING APPROACH FOR TREATING RETINOPATHY OF PREMATURITY  
M.A. Martínez-Castellanos, B. Aboites
- 91** SURGICAL MANAGEMENT OF NORRIE DISEASE AND X-LINKED FEVR  
K.A. Drenser
- 92** MANAGEMENT OF CICATRICLE RETINOPATHY OF PREMATURITY ROP  
E.N. El Rayes
- 93** DISPARITIES IN GENETIC DETECTION RATES BETWEEN AFRICAN AMERICAN AND NON-HISPANIC WHITE PATIENTS WITH INHERITED RETINAL DISEASES  
K.T. Jayasundera
- 94** SAFETY AND EFFICACY OF GENE THERAPY FOR PDE6A RELATED RETINITIS PIGMENTOSA  
M.D. Fischer, F. Reichel, K. Stingl, I.P. Seitz, S. Michalakis, B. Wilhelm, T. Peters, K.U. Bartz-Schmidt, S. Kohl, K. Stingl, L. Kuehlewein, E. Zrenner, M. Ueffing, M. Biel, B. Wissinger, on behalf of the RD-CURE Consortium
- 95** VAMIKIBART: TARGETING IL-6 SIGNALING TO TACKLE INFLAMMATION IN RETINAL DISEASE  
M. Mesquida, Z. Barekati, F. Storti, M. Pauly-Evers, R. Peck, W. Holmes, S. Fauser
- 96** CHORIOCAPILLARITIS, RESCUED FROM THE USELESS AND INAPPROPRIATE MISNOMER OF WHITE DOT SYNDROMES (WDS): DIAGNOSIS, CHARACTERIZATION, CLASSIFICATION MANAGEMENT AND OUTCOMES  
C.P. Herbort Jr., I. Papasavvas
- 97** MACROPHAGES-LIKE CELLS INCREASE IN VIVO IN ACTIVE UVEITIS AND RESPOND TO ANTI-INFLAMMATORY TREATMENT  
F. Pichi, E. Carreño

09:25-10:20

## AWARD SESSION

**YASUO TANO LECTURE: MASAHITO OHJI**

**MIKE TRESE AWARD: ANTONIO CAPONE**

**GRAGODAS AWARD: PIERRE-HENRY GABRIELLE**

10:20-10:40

## BREAK

10:40-12:25

## SESSION XIII

### CLINICAL AND EXPERIMENTAL STUDIES

- 98** RE-TREATMENT WITH SELECTIVE RETINA THERAPY (SRT) FOR CHRONIC CENTRAL SEROUS CHORIORETINOPATHY AND FOLLOW-UP OF RPE LESIONS MORPHOLOGY  
C. Framme, M. Lindziute, M. Binter, N. Al Mahamed, A. Pielen, J. Tode, and SRT Study Group
- 99** BASELINE CHARACTERISTICS RELATED TO VISUAL ACUITY AFTER PHOTODYNAMIC THERAPY FOR EYES WITH CENTRAL SEROUS CHORIORETINOPATHY  
T. Sakamoto, R. Funatsu, H. Terasaki
- 100** MYOCARDIAL INFARCTION AND STROKE AFTER INTRAVITREAL INJECTION OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR IN A NATIONAL STUDY  
C. Creuzot-Garcher, C. Conese, E. Benzenine, A.S. Mariet, F. Baudin, I. Ben Ghezala, P.H. Gabrielle, A.M. Bron, C. Quantin
- 101** GENETIC RISK FOR EXTRAMACULAR DRUSEN AND AGE-RELATED MACULAR DEGENERATION  
R. Silva, M.B. Machado, I. Figueiredo, R. Coimbra, P. Barreto, M.L. Cachulo, C. Farinha, J.G. Cunha-Vaz
- 102** ORAL METFORMIN INHIBITS CHOROIDAL NEOVASCULARIZATION BY MODULATING THE GUT-RETINA AXIS  
D. Skondra
- 103** LONG-TERM SAFETY AND BIOCOMPATIBILITY OF AFLIBERCEPT-LOADED MICROSPHERE-HYDROGEL DRUG DELIVERY SYSTEM  
J.J. Kang-Mieler, B.D. Story, S. Park, K. Roszak, J. Shim, M. Motta, M. Ferneding, K.M. Rudeen, G. Yiu, W.F. Mieler, S. Thomasy
- 104** SAFETY AND EFFICACY OF CRIZANLIZUMAB IN THE FATAL AUTOSOMAL DOMINANT FAMILIAL DISEASE RETINAL VASCULOPATHY AND CEREBRAL LEUKOENCEPHALOPATHY  
R.S. Apte, W.X. Wang, D. Spiegelman, P.K. Rao, A. Ford
- 105** PROLIFERATIVE VITREORETINOPATHY REVISITED - NEW INSIGHTS FROM OMICS STUDIES  
C. Lange, Y. Laich, J. Wolf, S. Boneva
- 106** USE OF SERIAL INTRAVITREAL METHOTREXATE INJECTIONS TO COMBAT RECURRENT PROLIFERATIVE VITREORETINOPATHY IN A PEDIATRIC PATIENT  
P.J. Ferrone, G. Jiao
- 107** DIVERSE AUTOREGULATION IN MACULAR AND PERIPHERAL VESSELS MAY EXPLAIN REGIONAL VARIATIONS IN THE RESPONSE PATTERN OF RETINAL VASCULAR DISEASE  
T. Bek
- 108** SUPRACHOROIDAL IMPLANTATION OF CORTICOSTEROID SLOW RELEASE IMPLANTS FOR THE TREATMENT OF CYSTOID MACULAR EDEMA  
S.G. Priglinger, J.B. Schiefelbein, F. Kruse, B. Schworm, J. Siedlecki, B. Asani

# Preliminary Scientific Programme

---

- 109** CARDIAC-INDUCED ORBITAL VASCULAR MOVEMENTS DURING B SCAN IMAGING: METAMORPHOSIA TO LIFE THREATENING  
Y. Fisher, M. Engelbert
- 110** ABSORPTION OF MACULAR HOLE OEDEMA IS FACILITATED BY UPRIGHT POSITIONING  
V. Forsaa, B. Lindtjørn, K. Dalø, J. Krohn
- 111** BILATERAL SEQUENTIAL PARACENTRAL ACUTE MIDDLE MACULOPATHY ASSOCIATED WITH LASER TREATMENT IN A PATIENT SUFFERING FROM PROLIFERATIVE SICKLE CELL RETINOPATHY AND DIABETES MELLITUS  
A. Ebnetter
- 112** CASE REPORT: CYTOMEGALOVIRUS RETINITIS IN AN HIV-NEGATIVE PATIENT WITH HISTORY OF CHRONIC LYMPHOPROLIFERATIVE DISEASE  
M. Lukic, I. Yeung, M. Westcott

12:25

**ADJOURN, END OF MEETING**



# Contact information

[www.mallorca.clubjulesgonin.es](http://www.mallorca.clubjulesgonin.es)

For any enquiry regarding membership, programme and abstracts:

Club Jules Gonin  
15 avenue de France 1004 Lausanne, Switzerland  
[info@clubjulesgonin.com](mailto:info@clubjulesgonin.com)

For any enquiry regarding organization, registration and accommodation:

Versal&Cyex Congress Services  
Email: [info@mallorca.clubjulesgonin.es](mailto:info@mallorca.clubjulesgonin.es)  
Phone: +34 902 102 976

